Title: Professor of Instruction
Department: Risk, Insurance, and Healthcare Management
Office: Alter 618
Research Interests: Pharmaceutical sales, Brand to generic substitutions, Pharmaceutical business performance
Dr. Chressanthis’s Curriculum Vitae
Dr. George Chressanthis brings a unique combination of professional experiences into the analysis of pharmaceutical issues. He is a former senior executive in the pharmaceutical industry with achievements in academia holding senior professorships in healthcare management, marketing, economics, and political science. He is currently a Professor of Healthcare Management and Marketing, and Director of the Center for Healthcare Research and Management in the Fox School of Business at Temple University, positions held since July 2010, and a Professor in the Department of Clinical Sciences at the Temple University School of Medicine, a position held since January 2014.
Read More . . .
Prior to starting at Temple University, he was Senior Director for Commercial Strategic Analysis at AstraZeneca Pharmaceuticals working at their US headquarters in Wilmington, DE for a career there that spanned 9.5 years. Before that he led for a number of years US Sales Force Strategy, Sales Operations, and Sales Analytics for AstraZeneca. Other department leadership positions involved Managed Markets Center of Excellence and Promotion Response Analytics at AstraZeneca. His pharmaceutical expertise covers the functional areas of generic bioequivalent and therapeutic substitution, effects due to increasing sales representative access limits to physicians, state pharmacy drug product selection laws, sales force optimization and sales operations, sales force effectiveness, promotion response and marketing-mix analysis, pricing, economics of public policy, managed markets analytics, and R&D pipeline productivity analysis. Other pharmaceutical work experiences include positions at Wyeth-Ayerst Laboratories, IMS Health, and ZS Associates for a total drug industry career spanning approximately 14.5 years.
Prior to his pharmaceutical industry career, Dr. Chressanthis was a tenured Professor of Economics and Associate Professor of Political Science with graduate faculty status at Mississippi State University. He held other faculty positions at Texas Tech University and Saginaw Valley State College, and respectively was awarded visiting research and scholar appointments at SUNY-Albany and the University of Michigan for a total first academic career spanning 14 years. He holds a Ph.D. and M.S. in Economics from Purdue University and a B.A. in Economics from Indiana University of Pennsylvania.
- Chressanthis, G., Khedkar, P., Jain, N., Poddar, P., & Seiders, M. (2013). Suppressing commercial speech is not in the best interests of physicians and patients. Journal of Clinical Hypertension, 14(3), 219-220. Published online December 10, 2012.
- Chressanthis, G., Khedkar, P., Jain, N., Poddar, P., & Seiders, M. (2012). Can access limits on sales representatives to physicians affect clinical prescription decisions? A study of recent events with diabetes and lipid drugs. Journal of Clinical Hypertension, 14(7) , 435-446.
- Chressanthis, G., Khedkar, P., Jain, N., Poddar, P., & Seiders, M. (2011). Generic to branded drug switch-back patterns: Exploratory analysis and insights from the statin class. Journal of Pharmaceutical Health Services Research, 2(4), 217-226. Published online September 25, 2011.
Awards and Honors
- Awarded secondary appointment as Professor, Department of Clinical Science. Temple University School of Medicine. 2014.
- Appointed Associate Editor, The American Economist, the official peer-reviewed publication of Omicron Delta Epsilon, the international honor society in economics. 2012.
- Appointed to Commercial Operations Division Leadership Team. AstraZeneca. 2008.
- Indiana University of Pennsylvania Distinguished Alumni Award. 2005.
- Promoted to Professor of Economics. Mississippi State University. 1995.
- Promoted to Associate Professor of Economics, awarded Associate Professor of Political Science, and granted tenure. Mississippi State University. 1990.
Fox School of Business, Temple University
- AS 5105, Actuarial Economics (Masters)
- BA 5801, Industrial Organization and Corporate Strategy (EMBA)
- HM 4596, Healthcare Quality and Risk Management (Undergraduate)
- HM 5102, Management of Healthcare Organizations (Masters)
- MKT 3504, Sales and Sales Management (Undergraduate)
- MKT 5001, Marketing Management and Strategy (MBA)
In the News
- News Works, "Endo Lobbies Congress for Additional Tests to Prove Generics' Quality"
- News Works, "Drugmaker Teva Halts Plan for Northeast Hub in Philly"
- News Works, "Pharma Giant Teva Will Lay off 10% of Global Workforce"
- News Works, "Yes, Pfizer Wants to Take Over AstraZeneca"
- News Works, "Delaware and Maryland Governors Want Answers from Pfizer"
- WHYY Newsworks, “AstraZeneca rejects Pfizer's 'final' takeover bid”
- WHYY Newsworks, “Job jitters over possible Pfizer takeover of AstraZeneca”
- Forbes, “Do Pharmaceutical Salespeople Sometimes Make Patients Safer?”
- Policy and Medicine, “Study Shows Restricting Sales Reps Access May Be Dangerous to Your Health”
- WHYY-TV, “First” program, “The Battle over AZ”